Resumes
Resumes
Jay Tischfield Phones & Addresses
-
Martinsville, NJ
-
Indianapolis, IN
-
9982 Mill Run, Carmel, IN 46032 (317) 848-3465
-
Cleveland Heights, OH
-
Somerset, NJ
-
Bridgewater, NJ
-
Pompano Beach, FL
-
Piscataway, NJ
-
4 Adams Ct, Martinsville, NJ 08836 (732) 271-4632
Work
Position:
Educator
Education
Degree:
Graduate or professional degree
Publications
Wikipedia
Jay Tischfield
View pageJay Tischfield is MacMillan Professor and the Chair of the Department of Genetics at Rutgers University. He also is the scientific director of the Rutgers University Cell ...
Us Patents
Alleles Of The Human Mu Opioid Receptor And Diagnostic Methods Based Thereon
View pageUS Patent:
6335168, Jan 1, 2002
Filed:
Jul 9, 1999
Appl. No.:
09/351198
Inventors:
Mary Jeanne Kreek - New York NY
Karl Steven LaForge - New York NY
Lei Yu - Cincinnati OH
Jay A. Tischfield - Carmel IN
Karl Steven LaForge - New York NY
Lei Yu - Cincinnati OH
Jay A. Tischfield - Carmel IN
Assignee:
The Rockefeller University - New York NY
The Advanced Research and Technology Institute, Inc. - Bloomington IN
The Advanced Research and Technology Institute, Inc. - Bloomington IN
International Classification:
C12Q 168
US Classification:
435 6, 536 235
Abstract:
Provided herein are variant alleles of a gene encoding a mu opioid receptor, along with cloning vectors for replicating such variant alleles, expressing vectors for expressing the variant alleles to produce variant mu opioid receptors, and antibodies to such variant receptors. Also disclosed are binding characteristics of such variant receptors regarding binding to opioid ligands, and the using of such binding characteristics to diagnose a subjects susceptibility to pain, susceptibility to an addictive disease, selecting an appropriate pain reliever along with a therapeutically effective amount of the reliever to administer to a subject suffering from pain. In addition, diagnostic methods for diagnosing a disease or disorder such as infertility, constipation, diarrhea, decreased immune response relative to a standard, and decreased ability to withstand stress relative to a standard, along with commercial kits for diagnosing such diseases or disorders. Furthermore, the invention is also directed to identification of targeted prevention methods, early therapeutic intervention, and improved treatment of opioid addiction, infertility, constipation, diarrhea, impaired immune responsiveness, and stress.
Alleles Of The Human Mu Opioid Receptor, Diagnostic Methods Using Said Alleles, And Methods Of Treatment Based Thereon
View pageUS Patent:
6337207, Jan 8, 2002
Filed:
Jul 10, 1998
Appl. No.:
09/113426
Inventors:
Mary Jeanne Kreek - New York NY
Karl Steven LaForge - New York NY
Lei Yu - Cincinnati OH
Jay A. Tischfield - Carmel IN
Karl Steven LaForge - New York NY
Lei Yu - Cincinnati OH
Jay A. Tischfield - Carmel IN
Assignee:
The Rockefeller University - New York NY
The Advanced Research and Technology Institute, Inc. - Bloomington IN
The Advanced Research and Technology Institute, Inc. - Bloomington IN
International Classification:
C12N 1563
US Classification:
4353201, 536 235, 435325
Abstract:
Provided herein are variant alleles of a gene encoding a mu opioid receptor, along with cloning vectors for replicating such variant alleles, expressing vectors for expressing the variant alleles to produce variant mu opioid receptors, and antibodies to such variant receptors. Also disclosed are binding characteristics of such variant receptors regarding binding to opioid ligands, and the using of such binding characteristics to diagnose a subjects susceptibility to pain, susceptibility to an addictive disease, selecting an appropriate pain reliever along with a therapeutically effective amount of the reliever to administer to a subject suffering from pain. In addition, diagnostic methods for diagnosing a disease or disorder such as infertility, constipation, diarrhea, decreased immune response relative to a standard, and decreased ability to withstand stress relative to a standard, along with commercial kits for diagnosing such diseases or disorders.
Mammalian Phospholipase A2 Nucleotide Sequences, Low Molecular Weight Amino Acid Sequences Encoded Thereby, Antisense Sequences And Nucleotide Sequences Having Internal Ribosome Binding Sites
View pageUS Patent:
6352849, Mar 5, 2002
Filed:
Jul 28, 1999
Appl. No.:
09/362230
Inventors:
Jay A. Tischfield - Carmel IN, 46032
Jeffrey J. Seilhamer - Los Altos Hills CA
Jeffrey J. Seilhamer - Los Altos Hills CA
Assignee:
Jay A. Tischfield - Piscataway NJ
Incyte Pharmaceuticals, Inc. - Palo Alto CA
Incyte Pharmaceuticals, Inc. - Palo Alto CA
International Classification:
C12N 1555
US Classification:
435198, 536 232, 4353201, 4352523, 435325
Abstract:
Novel mammalian phospholipase (PLA ) nucleotide sequences and low molecular weight (about 14 KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA cDNA expressing HPLA -10 and its cloned rat RPLA cDNA counterpart, expressing RPLA -10, which are characterized as PLA Type IV, are disclosed. A second type of PLA cDNA, characterized as PLA Type III and exemplified by a rat PLA cDNA encoding RPLA -8 and a partial human PLA nucleotide sequence encoding HPLA -8, is disclosed. Expression of the cDNAs encode the two new types of PLA enzymes which have phospholipase activity. The novel PLA s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14 KD PLA s are believed to be conserved in RPLA -8 and HPLA -8, whereas all eighteen are believed to be conserved in RPLA -10 and HPLA -10.
Compositions And Methods For High-Throughput Nucleic Acid Analysis And Quality Control
View pageUS Patent:
20130178376, Jul 11, 2013
Filed:
Aug 8, 2011
Appl. No.:
13/814619
Inventors:
Jay A. Tischfield - Martinsville NJ, US
Andrew I. Brooks - New York NY, US
Andrew I. Brooks - New York NY, US
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - New Brunswick NJ
International Classification:
C12Q 1/68
US Classification:
506 7, 506 16
Abstract:
Methods for improved quality control of nucleic acid containing biological samples utilized in high-throughput situations such as biorepositories engaged in the collection, processing, storage, distribution and analysis of such samples are disclosed.
Mammalian Phospholipase A.sub.2 Nucleotide Sequences Low Molecular Weight Amino Acid Sequences Encoded Thereby Antisense Sequences And Nucleotide Sequences Having Internal Ribosome Binding Sites
View pageUS Patent:
59726776, Oct 26, 1999
Filed:
Jul 7, 1997
Appl. No.:
8/888497
Inventors:
Jay A. Tischfield - Carmel IN
Jeffrey J. Seilhamer - Los Altos Hills CA
Jeffrey J. Seilhamer - Los Altos Hills CA
Assignee:
Incyte Pharmaceuticals, Inc.
International Classification:
C12N 920
C12N 1555
C12N 1555
US Classification:
435198
Abstract:
Novel mammalian phospholipase (PLA. sub. 2) nucleotide sequences and low molecular weight (about 14KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA. sub. 2 cDNA expressing HPLA. sub. 2 -10 and its cloned rat RPLA. sub. 2 cDNA counterpart, expressing RPLA. sub. 2 -10, which are characterized as PLA. sub. 2 Type IV, are disclosed. A second type of PLA. sub. 2 cDNA, characterized as PLA. sub. 2 Type III and exemplified by a rat PLA. sub. 2 cDNA encoding RPLA. sub. 2 -8 and a partial human PLA. sub. 2 nucleotide sequence encoding HPLA. sub. 2 -8, is disclosed. Expression of the cDNAs encode the two new types of PLA. sub. 2 enzymes which have phospholipase activity. The novel PLA. sub. 2 s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops.
Live Mouse Mutagenesis Systems For Testing Mutagenic Agents In Vivo
View pageUS Patent:
60546336, Apr 25, 2000
Filed:
Jun 5, 1995
Appl. No.:
8/461607
Inventors:
Jay A. Tischfield - Carmel IN
Peter J. Stambrook - Cincinnati OH
Peter J. Stambrook - Cincinnati OH
Assignee:
University of Cincinnati - Cincinnati OH
International Classification:
A01K 67027
A01K 6900
C12N 1500
A01K 6900
C12N 1500
US Classification:
800 18
Abstract:
Novel transgenic nonhuman animals, such as transgenic mice, for detecting and characterizing mutations in vivo are disclosed. When detecting reverse mutations, such as mutations of the APRT gene, the transgenic nonhuman animal now afford the unique advantage of detecting and characterizing mutations in vivo without having to sacrifice the animals as required heretofore. Moreover, since the transgenic nonhuman animals do not need to be sacrificed, they provide the unique opportunity to correlate the incidence and location of tumors (carcinogenesis) with the incidence and location of mutagenesis. Also disclosed are novel constructs, cell lines and chimeric animals for producing the novel transgenic animals. Novel methods for detecting and characterizing the mutations in vivo and producing animals for use in accordance with the methods of the instant invention are disclosed.
Live Mouse Mutagenesis Systems For Testing Mutagenic Agents In Vivo
View pageUS Patent:
62325248, May 15, 2001
Filed:
Jul 29, 1999
Appl. No.:
9/363600
Inventors:
Jay A. Tischfield - Piscataway NJ
Peter J. Stambrook - Cincinnati OH
Peter J. Stambrook - Cincinnati OH
International Classification:
A01K 67027
A01K 6900
A01K 6900
US Classification:
800 18
Abstract:
Novel transgenic nonhuman animals for detecting and characterizing mutations in vivo are disclosed. When detecting reverse mutations, the transgenic nonhuman animal now afford the unique advantage of detecting and characterizing mutations in vivo without having to sacrifice the animals as required heretofore. Moreover, since the transgenic nonhuman animals do not need to be sacrificed, they provide the unique opportunity to correlate the incidence and location of tumors (carcinogenesis) with the incidence and location of mutagenesis. Also disclosed are novel constructs, cell lines and chimeric animals for producing the novel transgenic animals. Novel methods for detecting and characterizing the mutations in vivo and producing animals for use in accordance with the methods of the instant invention are disclosed.